Molecular Partners AG - ADR Aktie News

Swiss biotech firm Molecular Partners said on Tuesday that it plans to reduce its workforce by up to 40 positions, or around 24%, as part of a strategic review to boost operational efficiency and focus on key clinical assets.

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announces that it has performed a strategic review of its c...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that members of the management team will participate in two upcoming investor conferences.

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of three posters at the America...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that all motions proposed by the Board of Directors at the Annual General meeting were appr...

Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212 Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2025.

Molecular Partners AG (NASDAQ:MOLN ) Q4 2024 Earnings Conference Call March 7, 2025 8:00 AM ET Company Participants Michael Tobias Stumpp - EVP Projects Patrick Amstutz - Co-Founder & CEO Philippe Legenne - Chief Medical Officer Robert Hendriks - SVP Finance Seth Lewis - SVP Investor Relations, Communications and Strategy Conference Call Participants Jonathan Chang - Leerink Partners Richard Vo...